Amgen 3Q09 3Q Revenues: $3.8 billion (flat) 3Q Earnings: $1.4 billion (+23%) YTD Revenues: $10.8 billion (-4%) YTD Earnings: $3.7 billion (+17%) Comments: Product sales fell 1% in 3Q09 to $3.7 billion; U.S. sales were flat at $2.9 billion. Enbrel sales climbed 3% to $924 million, with a price increase offsetting a drop in unit sales in dermatology. Aranesp sales fell 19% to $685 million in the quarter, while Epogen rose 5% to $663 million. Neulasta and Neupogen sales grew 2% to $1...